CEO at Super Bock Group since 2015, Rui has joined the company in 2006 as CFO to later become Deputy CEO (2013).
With a 20-year long career in the banking industry (Banco BPI), he has background and experience in several areas, namely corporate finance, corporate banking, and private equity.
On top of his degree in Economics at FEP – Faculdade de Economia do Porto, Rui Lopes Ferreira has top management training at INSEAD (Advanced Management Program) and Harvard Business School (Senior Executive Leadership Program).
Holding relevant roles in various institutions in the region, namely being member of the Supervisory Board at Porto Business School and APGEI – Associação Portuguesa de Gestão e Engenharia Industrial.
Rui was Chairman of Cervejeiros de Portugal during the period of 2015 to 2018 has been recently reappointed as its Chairman (2023).
Emanuel Schäpper, is responsible for ELPRO’s global business management with key pharmaceutical companies and thus involved in many temperature monitoring projects in healthcare logistics. He has over 25 years experiences in sales, marketing and key account management, including 9 years at ELPRO. Emanuel is based at the company’s headquarters’ in Switzerland and holds a Master’s degree in economics and information management from University of Sankt Gallen Switzerland.
Patrik Senn, Head of Product Management at ELPRO, specializes in aligning the pharmaceutical industry’s demands with the development of temperature monitoring solutions. His career spans roles from Development Engineer to Project Manager, showcasing his versatility in project leadership and team management. Based in Switzerland, Patrik holds a Bachelor of Science in Business Administration and Engineering, reflecting his blend of technical skill and business acumen.
Highly regarded as something of a maverick within the drinks industry, Emma Wykes is a unique and inspirational leader with over 25 years of experience as an innovator and world-class leader in the field.
Emma was one of the founders of the non-alcoholic drinks category, leading the ground-breaking brand Seedlip through its first 5 years of growth and development and subsequent acquisition by Diageo. As Chief Operating Officer, with a spell as interim CEO, Emma was instrumental in Seedlip’s ascension from a niche non-alcoholic spirit to one of the most influential and transformative brands in the global drinks space.
Harnessing her unique management prowess, Emma implemented data driven processes whilst shaping a dynamic and inclusive company culture and environment that nurtured an intuitive and entrepreneurial spirit – a spirit that supported Seedlip’s rise to iconic status and created a whole new drinks category that revolutionised the global drinks market.
Prior to Seedlip, Emma worked with cutting edge agency, Marblehead Brand Development climbing through the ranks from Distributor to her first Managing Director Role in 2013. Emma managed Marblehead through a joint venture and acquisition by the Quintessential Brand Group in 2015, attracting top-class talent and expanding their portfolio to include several new brands including Don Papa Rum and the QB Gin portfolio (Bloom, Opihr).
A natural innovator, Emma was also at the start of the Gin renaissance in 1999 where, as Global Head of Sales and Marketing for Martin Millers Gin, she launched and grew the brand from a UK brand to an International one with accounts across Europe, US and Australia.
With a unique approach to work and life, Emma established a solid career path before completing a degree in Psychology and Philosophy through the Open University following the birth of her daughter Isobel in 2011. In 2022, she qualified as an ACC coach with the International Coaching federation, a role that proved key in the development of the team at Seedlip, teaching everyone how to be accountable, responsible and to self-solve.
Tim Akers is a Subject Matter Expert at Medidata, focusing in Clinical Trial Innovation. His background surrounds various roles within the lifecycle of clinical research. He has vast experience as a monitor on multiple late stage trials primarily in Oncology. He also has experience as a Project manager in Early Clinical Development. During his time at a large CRO, he helped develop strategic Vendor Management initiatives focusing on controlling and improving how business is conducted with 3rd party vendors in an outsourced clinical trial. Tim has unique experience as he transitioned to a commercially focused role, focused on helping biotech and mid-market customers graduate through IND enabling and into First in Human trials. During his time at Medidata, Tim has played a leadership role in the development of Medidata’s vision for CTMS, eTMF, and RBQM by helping clients redesign their Platform model and innovative approaches to Study team workflows. He now leads a team of SME’s focused on Central Data aggregation, standardization, and analytics.
Mark Kalhøj Andersen is a leader with extensive experience in technology and commerce. With a foundation in Chemistry and Environmental Engineering from Aalborg University, blended with strategic business education of a Graduate Diploma in Business Administration (GDBA) in Organization and Leadership, focusing on Marketing Management.
April 2024, Mark has taken a new role as CEO of Lyras A/S, with a continued focused effort on driving growth, improving order intake, and boosting revenue.
• Our mission is to serve customers around the world in the food, beverage, dairy processing, and fermentation industries to enable energy and water reduction.
• Value creation at our customers is key and our systems will secure profitability and short return on investment alongside the positive sustainability impact.
• Our strategy for the next three years is based on strengthening our position in key industries while focusing on elements to accelerate growth, profitability and serve our clients.
Since 2022, Mark has been leading commercial operations at Lyras A/S, serving as the Chief Commercial Officer actively generating a comprehensive global sales and marketing strategy. Mark’s responsibilities extended across the establishment and management of global sales offices, the creation and maintenance of distributor networks, and fostering productive relationships with engineering and OEM partners.
Previously Mark worked as the Technical Director at DESMI Ocean Guard A/S. There, he led the commercial and technical sides of the business, overseeing technical functions, managing customer projects, and steering organizational development. His role prior to that as Technical Manager highlighted his capabilities in project preparation, product development, and managing critical customer projects. Mark’s career trajectory is characterized by a blend of technical depth and commercial insight, positioning him as a key figure in shaping the future of the current organization and the industry.
Kathleen Greenough, Vice President of Marketing & Commercial Operations at 4G Clinical, has decades of experience in life sciences spanning Clinical Operations, Finance, and IT. Her wide range of solutions implementation expertise includes RTSM, CTMS, trial costing tools, OLAP financial suites and patient enrollment planning. Kathleen has also spent many years as a Clinical Financial Planner and Analyst at a major biotech in Cambridge, MA, gaining a broad and deep understanding of the challenges inherent in Clinical Development. Specializing in software adoption and a frequent speaker at industry conferences, Kathleen is most in her element when working within a user community to facilitate solutions that are insightful and truly helpful.
Dr. Gerald Y. Minuk, Professor Emeritus at the University of Manitoba in Winnipeg, Canada, is the founder of Refuah Solutions Ltd. Dr. Minuk has over 40 years of experience in the medical field and is highly qualified as an experienced clinical trials investigator and clinician. At Refuah, Dr. Minuk and his global colleagues have applied their vast experience in clinical medicine to assisting other investigators in their efforts to improve patient recruitment/retention, limit screen failures, maximize study awareness and generate high quality data.
Carleen joined Gravitas Medical as the Clinical Operations Lead in March 2023 after three years at Verily Life Sciences, where she quickly advanced from coordinator to Clinical Trial Manager for medical devices. She currently oversees all aspects of Clin Ops at Gravitas, including the conduct of multiple NIH-funded multisite studies. Carleen also spearheaded Gravitas’ receipt of two FDA Breakthrough Device Designations in 2023 for the Gravitas Feeding Tube System. Carleen regularly draws from her clinical and patient care experience as an EMT and Clinical Research Coordinator at Stanford to develop and operate efficient in-hospital studies. Carleen attended University of Washington, where she studied Medical Anthropology & Global Health and Spanish, and continues to be passionate about improving public health and addressing health disparities. In her freetime, Carleen is a Pure Barre instructor and enjoys traveling.
